HC Wainwright restated their buy rating on shares of Tempest Therapeutics (NASDAQ:TPST – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. They currently have a $47.00 price objective on the stock. HC Wainwright also issued estimates for Tempest Therapeutics’ Q1 2024 earnings at ($0.36) EPS, Q2 2024 earnings at ($0.36) […]
Tempest Therapeutics (NASDAQ:TPST – Free Report) had its price target lifted by HC Wainwright from $35.00 to $47.00 in a report published on Wednesday morning, Marketbeat reports. HC Wainwright currently has a buy rating on the stock. Tempest Therapeutics Trading Down 8.5 % TPST opened at $3.64 on Wednesday. The stock has a market capitalization […]
Tempest Therapeutics (NASDAQ:TPST – Get Free Report) had its price target lifted by research analysts at HC Wainwright from $35.00 to $47.00 in a research note issued to investors on Wednesday, Marketbeat reports. The brokerage presently has a “buy” rating on the stock. Tempest Therapeutics Stock Down 59.3 % Shares of TPST stock opened at […]
Tempest Therapeutics, Inc. (NASDAQ:TPST – Get Free Report) saw a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 85,000 shares, an increase of 161.5% from the August 31st total of 32,500 shares. Based on an average trading volume of 138,900 shares, the days-to-cover ratio […]